<?xml version="1.0" encoding="UTF-8"?>
<p>In Kenya, 3,215,116 of 
 <italic>Plasmodium falciparum</italic> were reported in the year 2017. Furthermore, the World Health Organization [
 <xref rid="B1" ref-type="bibr">1</xref>] projected that over 3.2 billion individuals residing in 91 countries are at a high risk of contracting malaria infection. In view of the rising statistics, the high mortality rates of malaria subjects are of great concern. As a result, the Global Technical Strategy for Malaria aims at reducing malaria incidences and mortalities by at least 40% before the year 2020 [
 <xref rid="B1" ref-type="bibr">1</xref>]. Many reports have indicated an increase in conventional antimalarials by the parasites [
 <xref rid="B2" ref-type="bibr">2</xref>, 
 <xref rid="B3" ref-type="bibr">3</xref>]. Moreover, associated toxicities and adverse events caused by conventional antimalarial drugs make them ineffective in malaria therapy, warranting an urgent need for alternative and complementary approaches [
 <xref rid="B4" ref-type="bibr">4</xref>]; [
 <xref rid="B5" ref-type="bibr">5</xref>].
</p>
